73 related articles for article (PubMed ID: 20944681)
1. Development of murine leukemia virus-based retroviral vectors with a minimum possibility of cis-activation.
Jang J; Lee JT; Lee K; Kim S; Kim JY; Yoon K; Kim S
Gene Ther; 2011 Mar; 18(3):240-9. PubMed ID: 20944681
[TBL] [Abstract][Full Text] [Related]
2. Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches.
Brandtner EM; Kodajova P; Hlavaty J; Jandl G; Tabotta W; Salmons B; Günzburg WH; Hohenadl C
J Gene Med; 2008 Feb; 10(2):113-22. PubMed ID: 18076132
[TBL] [Abstract][Full Text] [Related]
3. Retroviral vectors for the transduction of autoregulated, bidirectional expression cassettes.
Unsinger J; Kröger A; Hauser H; Wirth D
Mol Ther; 2001 Nov; 4(5):484-9. PubMed ID: 11708885
[TBL] [Abstract][Full Text] [Related]
4. Optimization of regulated LTR-mediated expression.
Lorens JB; Jang Y; Rossi AB; Payan DG; Bogenberger JM
Virology; 2000 Jun; 272(1):7-15. PubMed ID: 10873744
[TBL] [Abstract][Full Text] [Related]
5. Expression of human glucocerebrosidase in murine macrophages: identification of efficient retroviral vectors.
Freas-Lutz DL; Correll PH; Dougherty SF; Xu L; Pluznik DH; Karlsson S
Exp Hematol; 1994 Aug; 22(9):857-65. PubMed ID: 8062885
[TBL] [Abstract][Full Text] [Related]
6. Genetic reshuffling reconstitutes functional expression cassettes in retroviral vectors.
Tabotta W; Klein D; Hohenadl C; Salmons B; Günzburg WH
J Gene Med; 2001; 3(5):418-26. PubMed ID: 11601755
[TBL] [Abstract][Full Text] [Related]
7. Hybrid HIV/MSCV LTR enhances transgene expression of lentiviral vectors in human CD34(+) hematopoietic cells.
Choi JK; Hoang N; Vilardi AM; Conrad P; Emerson SG; Gewirtz AM
Stem Cells; 2001; 19(3):236-46. PubMed ID: 11359949
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy.
Byun J; Kim SH; Kim JM; Yu SS; Robbins PD; Yim J; Kim S
Gene Ther; 1996 Sep; 3(9):780-8. PubMed ID: 8875226
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system.
Chang LJ; Urlacher V; Iwakuma T; Cui Y; Zucali J
Gene Ther; 1999 May; 6(5):715-28. PubMed ID: 10505094
[TBL] [Abstract][Full Text] [Related]
10. Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors.
Schambach A; Mueller D; Galla M; Verstegen MM; Wagemaker G; Loew R; Baum C; Bohne J
Gene Ther; 2006 Nov; 13(21):1524-33. PubMed ID: 16763662
[TBL] [Abstract][Full Text] [Related]
11. Engineering the splice acceptor for improved gene expression and viral titer in an MLV-based retroviral vector.
Lee JT; Yu SS; Han E; Kim S; Kim S
Gene Ther; 2004 Jan; 11(1):94-9. PubMed ID: 14681702
[TBL] [Abstract][Full Text] [Related]
12. Development of an in vitro cell culture assay system for measuring the activation of a neighbouring gene by the retroviral vector.
Hong Y; Yu SS; Yoon NK; Kang SJ; Lee JT; Kim S; Kim JM; Lee K; Jang JW; Kim S
J Gene Med; 2008 Aug; 10(8):847-54. PubMed ID: 18563862
[TBL] [Abstract][Full Text] [Related]
13. Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy.
Junker U; Böhnlein E; Veres G
Gene Ther; 1995 Nov; 2(9):639-46. PubMed ID: 8548553
[TBL] [Abstract][Full Text] [Related]
14. Construction of retroviral vectors with enhanced efficiency of transgene expression.
Hahm SH; Yi Y; Lee DK; Noh MJ; Yun L; Hwang S; Lee KH
J Virol Methods; 2004 Nov; 121(2):127-36. PubMed ID: 15381349
[TBL] [Abstract][Full Text] [Related]
15. Effects of sequences of prokaryotic origin on titer and transgene expression in retroviral vectors.
Hlavaty J; Portsmouth D; Stracke A; Salmons B; Günzburg WH; Renner M
Virology; 2004 Dec; 330(1):351-60. PubMed ID: 15527860
[TBL] [Abstract][Full Text] [Related]
16. Enhanced transgene expression in primitive hematopoietic progenitor cells and embryonic stem cells efficiently transduced by optimized retroviral hybrid vectors.
Ketteler R; Glaser S; Sandra O; Martens UM; Klingmüller U
Gene Ther; 2002 Apr; 9(8):477-87. PubMed ID: 11948372
[TBL] [Abstract][Full Text] [Related]
17. Transgene stability for three replication-competent murine leukemia virus vectors.
Duch M; Carrasco ML; Jespersen T; Hansen BD; Pedersen FS
Gene; 2004 Mar; 329():61-9. PubMed ID: 15033529
[TBL] [Abstract][Full Text] [Related]
18. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors.
Curran MA; Kaiser SM; Achacoso PL; Nolan GP
Mol Ther; 2000 Jan; 1(1):31-8. PubMed ID: 10933909
[TBL] [Abstract][Full Text] [Related]
19. T cell-specific expression from Mo-MLV retroviral vectors containing a CD4 mini-promoter/enhancer.
Zhao-Emonet JC; Marodon G; Pioche-Durieu C; Cosset FL; Klatzmann D
J Gene Med; 2000; 2(6):416-25. PubMed ID: 11199262
[TBL] [Abstract][Full Text] [Related]
20. High efficiency retroviral vectors that contain no viral coding sequences.
Yu SS; Kim JM; Kim S
Gene Ther; 2000 May; 7(9):797-804. PubMed ID: 10822307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
